Anticonvulsants

A seizure is a burst of abnormal, excessive, hypersynchronous firing by a population of neurons. Under the hood it reflects a broken balance between the brain’s excitatory drive — mainly glutamate, which depolarizes neurons by letting sodium and calcium in — and its inhibitory tone — mainly GABA, which hyperpolarizes them by letting chloride in.

When inhibition fails or excitation dominates, neurons depolarize too easily, fire in rapid bursts, and recruit their neighbors. The discharge spreads across the cortex, and what began as a local hyper-excitable focus becomes a clinical seizure. Every anticonvulsant, whatever its target, is trying to tip that balance back toward stability.

Anticonvulsants are a *heterogeneous* class — they don’t share one structure or one mechanism — but they cluster into three families. (1) Sodium-channel blockers — phenytoin, carbamazepine, lamotrigine — bind voltage-gated Na⁺ channels preferentially when they’re firing rapidly ("use-dependent" block), freezing the runaway focus while sparing normal traffic. (2) GABA enhancers — valproate, plus benzodiazepines and barbiturates — raise inhibitory tone. (3) Calcium-channel / vesicle modulators — levetiracetam binds the synaptic-vesicle protein SV2A to damp abnormal transmitter release; others block T-type calcium channels (absence seizures).

Valproate is called "broad-spectrum" because it works through several of these at once. The practical point for a nurse is that the *shared* action — quieting over-excitable neurons — predicts the *shared* side effects: sedation, dizziness, and ataxia across the whole class.

The adverse effects organize into two very different buckets, and telling them apart is the key clinical skill. Predictable, dose-related effects come straight from dampening neurons and from the narrow therapeutic window: sedation, dizziness, ataxia, nystagmus, and diplopia that worsen as the serum level climbs. This is why several of these drugs — phenytoin (10–20), carbamazepine (4–12), valproate (50–100 mcg/mL) — need serum-level monitoring; the gap between a working level and a toxic one is small, and phenytoin’s non-linear kinetics make the jump abrupt.

The second bucket is idiosyncratic — immune-mediated reactions that are largely *independent of dose* and often catastrophic. These drive the boxed warnings: severe skin reactions (Stevens-Johnson syndrome / TEN, linked to the **HLA-B\*1502 gene in patients of Asian ancestry), blood dyscrasias (carbamazepine aplastic anemia/agranulocytosis), and hepatotoxicity, pancreatitis, and teratogenicity** (valproate). A third, separate concern applies to *every* AED: a class-wide FDA warning (a Precaution, not a boxed warning) that antiepileptic drugs modestly increase suicidal thoughts and behavior, for any indication, as early as one week in.